Spyre Therapeutics, Inc.
AGLE
Revenue
0.00
0.000.00%
3 Months ChangeAssets
436.07M
▼-51.54M▼-10.57%
3 Months ChangeLiabilities
61.68M
▼-20.25M▼-24.71%
3 Months ChangeFree Cash Flow
-26.30M
▼-6.32M▼-31.63%
12 Months ChangeRevenue/Cost Of Revenue
Revenue
Cost Of Revenue
Loading...
| Date | Revenue | Cost Of Revenue |
|---|---|---|
Net Profit/Loss
Net Profit/Loss
Baseline
Loading...
| Date | Net Profit/Loss |
|---|---|
Assets/Liabilities
Assets
Liabilities
Loading...
| Date | Assets | Liabilities |
|---|---|---|
Cash Flows
Operating (Cash Flow)
Investing (Cash Flow)
Financing (Cash Flow)
Free Cash Flow
Loading...
| Date | Operating (Cash Flow) | Investing (Cash Flow) | Financing (Cash Flow) | Free Cash Flow |
|---|---|---|---|---|
EPS
EPS (Diluted)
Loading...
| Date | EPS | EPS (Diluted) |
|---|---|---|
Outstanding Shares
Loading...
| Date | Outstanding Shares |
|---|---|
Recent 8-K/10-Q Filings
2024-05-30
Form 8-K
ID: 0001193125-24-150395
2024-05-15
Form 8-K
ID: 0001193125-24-138893
2024-05-09
Form 8-K
ID: 0001636282-24-000039
2024-05-09
Form 10-Q
ID: 0001636282-24-000037
2024-04-25
Form 8-K
ID: 0001193125-24-113954
2024-03-18
Form 8-K
ID: 0001193125-24-069693
2024-02-29
Form 8-K
ID: 0001636282-24-000007
2024-02-05
Form 8-K
ID: 0001193125-24-023462
2024-01-18
Form 8-K
ID: 0001193125-24-010226
2023-12-08
Form 8-K
ID: 0001193125-23-291257